IQ-AI Limited
IQAI.L
London Stock Exchange0.83
GBp
- -
- -
IQ-AI Limited
IQAI.L
(London Stock Exchange)
Recent
price
0.83
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- IQ-AI Limited operates through its subsidiaries, delivering advanced software solutions and therapeutic developments to the healthcare sector, primarily across Jersey and the United States. Its portfolio features sophisticated software applications designed to enhance medical image analysis. These include IB Clinic, a suite of post-processing plug-ins for seamless integration into existing medical image visualization platforms. IB Rad Tech provides a powerful workflow engine, automating and customizing advanced medical imagery post-processing to boost efficiency. IB Neuro offers an exclusive MRI and CT perfusion platform, delivering quantitative relative cerebral blood volume maps essential for analyzing brain tumors, aiding in differentiation, grading, and distinguishing post-treatment effects. IB Delta Suite, a comprehensive image processing toolkit, is utilized for operations like image co-registration, subtraction, and the generation of quantitative Delta T1 maps for precise tumor identification and visualization. Furthermore, the company develops IB DCE for analyzing dynamic contrast-enhanced MRI images to produce perfusion and permeability parameters, and IB Diffusion for processing diffusion-weighted images to create various parameter maps, including apparent diffusion coefficient. Its offerings also extend to IB StoneChecker, a medical software tool assisting clinical decisions by providing critical kidney stone data, and IB LSN (Liver Surface Nodularity), a proprietary application granted FDA clearance for non-invasive assessment of chronic liver disease using CT images. More recently, the company has progressed with IB Zero G, an artificial intelligence model aimed at generating simulated contrast images from non-contrast inputs, with an FDA 510(k) application submitted. Beyond imaging diagnostics, IQ-AI is advancing in therapeutics with its oral gallium maltolate (GaM) therapy, currently undergoing a Phase 2 study for glioblastoma, having shown promising preliminary results in its Phase 1 trial and receiving breakthrough therapy designation application. The company continues to form strategic partnerships, broadening the reach of its AI-driven medical imaging technologies to a global client base, and remains based in Saint Helier, Jersey, having adopted the IQ-AI Limited name in October 2018.